Quarterly report pursuant to Section 13 or 15(d)

5. STOCKHOLDERS??? EQUITY (Tables)

v3.10.0.1
5. STOCKHOLDERS’ EQUITY (Tables)
9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Schedule of assumptions
  Nine Months Ended September 30,
  2018   2017
       
Expected term 5.8 - 6.3 years   5.8 - 6.3 years
Volatility 54-57%   58-64%
Dividend yield 0.0   0.0
Risk-free interest rate 2.40-2.97%   1.60-2.29%
Schedule of stock option activity
  Nine Months Ended
  September 30, 2018
  Shares   Weighted Average Exercise Price
       
Outstanding at beginning of period            3,276,043    $                 5.52
Forfeited               (46,285)    $                 4.05
Expired               (12,446)    $                 8.03
Granted            1,064,700    $                 3.99
Exercised                 (3,688)    $                 3.14
Outstanding at end of period and expected to vest            4,278,324    $                 5.15
       
Options exercisable            2,026,707    $                 6.51
Stock-based compensation expense
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
    2018   2017   2018   2017
                 
Research and development    $               84,588    $             141,405    $             246,231    $             262,822
Plasma centers                       7,836                     10,341                     22,682                     36,288
Selling, general and administrative                   444,651                   331,946                1,245,702                   726,062
Cost of product revenue                     40,506                     22,038                   113,141                     27,798
                 
Total stock-based compensation expense    $             577,581    $             505,730    $          1,627,756    $          1,052,970